Cargando…
High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma
INTRODUCTION: Multiple myeloma (MM) is still incurable due to resistance against various therapies. Thus, the identification of biomarkers predicting progression is urgently needed. Here, we evaluated four biomarkers in bone marrow and peripheral blood of MM patients for their prognostic significanc...
Autores principales: | Steiner, Normann, Hajek, Roman, Sevcikova, Sabina, Borjan, Bojana, Jöhrer, Karin, Göbel, Georg, Untergasser, Gerold, Gunsilius, Eberhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519162/ https://www.ncbi.nlm.nih.gov/pubmed/28727816 http://dx.doi.org/10.1371/journal.pone.0181487 |
Ejemplares similares
-
Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017) -
The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets
por: Steiner, Normann, et al.
Publicado: (2018) -
The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
por: Steiner, Normann, et al.
Publicado: (2020) -
Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78
por: Borjan, Bojana, et al.
Publicado: (2020) -
Marine compounds inhibit growth of multiple myeloma in vitro and in vivo
por: Steiner, Normann, et al.
Publicado: (2015)